1
|
Lee YK, Choi DO, Kim GY. Development of a Rapid Diagnostic Kit for Congestive Heart Failure Using Recombinant NT-proBNP Antigen. Medicina (B Aires) 2021; 57:medicina57080751. [PMID: 34440957 PMCID: PMC8398600 DOI: 10.3390/medicina57080751] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2021] [Revised: 07/13/2021] [Accepted: 07/22/2021] [Indexed: 12/04/2022] Open
Abstract
Background and Objectives: In patients with congestive heart failure, brain natriuretic peptide (BNP) and N-terminal prohormone of brain natriuretic peptide (NT-proBNP) are released due to excessive heart muscle expansion; they can be used for the early detection, progress monitoring, and treatment of congestive heart failure. Recently, considerable efforts have been made to develop an NT-proBNP-based biomarker for detecting heart failure. This study attempts to develop a rapid and accurate congestive heart failure diagnostic kit using NT-proBNP. Materials and Methods: A new gene based on NT-proBNP was selected, recombined, and expressed in Escherichia coli strains, and then monoclonal antibodies were produced using the hybridoma technique. Additionally, antigen-antibody reactivity was confirmed using indirect enzyme-linked immunosorbent assay (ELISA). Furthermore, the first pair and full-strip pair tests were conducted to select candidate clones; these were applied to a rapid diagnosis kit based on gold conjugates and compared with other currently available antigens. Results: NT-proBNP-based antigens with high specificity and monoclonal antibodies were produced, and the optimal antigen-antibody reactivity was confirmed using indirect ELISA. The first pair and full-strip pair tests were performed to select the optimal candidate clones, and a rapid diagnosis kit with excellent reactivity was developed by applying these to a rapid diagnosis kit based on gold conjugates. Conclusions: The development of this rapid diagnosis kit with excellent performance in congestive heart failure is expected to improve disease management by providing an early assessment of the risk of heart failure.
Collapse
Affiliation(s)
- Young-Ki Lee
- Department of Biomedical Laboratory Science, College of Health Sciences, Dankook University, 119 Dandae-ro, Dongnan-gu, Cheonan-si 31116, Chungnam, Korea;
| | - Dong-Ok Choi
- Bore Da BioTECH Co., LTD., 14, B-505, Sagimakgol-ro 45 beon-gil, Jungwon-gu, Seongnam-si 13209, Gyeonggi-do, Korea;
| | - Ga-Yeon Kim
- Department of Public Health, Graduate School, Dankook University, 119 Dandae-ro, Dongnan-gu, Cheonan-si 31116, Chungnam, Korea
- Correspondence: ; Tel.: +82-41-550-1493; Fax: +82-41-550-1490
| |
Collapse
|
2
|
Gasparyan AZ, Shlevkov NB, Skvortsov AA. [Possibilities of modern biomarkers for assessing the risk of developing ventricular tachyarrhythmias and sudden cardiac death in patients with chronic heart failure]. ACTA ACUST UNITED AC 2020; 60:101-108. [PMID: 32394864 DOI: 10.18087/cardio.2020.4.n487] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2019] [Revised: 03/15/2020] [Accepted: 01/29/2020] [Indexed: 11/18/2022]
Abstract
Current biomarkers allow diagnosing a wide array of pathological processes and evaluating effects of therapies and prognosis for cardiological patients. This review focuses on a possibility of using N-terminal pro-brain natriuretic peptide (NT-proBNP), soluble suppressor of tumorigenicity 2 (sST2), galectin-3, and other biomarkers in patients with chronic heart failure for evaluating the risk of life-threatening ventricular tachyarrhythmias and sudden cardiac death.
Collapse
Affiliation(s)
- A Zh Gasparyan
- Federal State Budget Organization National Medical Research Center of Cardiology, Ministry of Healthcare Russian Federation
| | - N B Shlevkov
- Federal State Budget Organization National Medical Research Center of Cardiology, Ministry of Healthcare Russian Federation
| | - A A Skvortsov
- Federal State Budget Organization National Medical Research Center of Cardiology, Ministry of Healthcare Russian Federation
| |
Collapse
|
3
|
Sardu C, Marfella R, Santamaria M, Papini S, Parisi Q, Sacra C, Colaprete D, Paolisso G, Rizzo MR, Barbieri M. Stretch, Injury and Inflammation Markers Evaluation to Predict Clinical Outcomes After Implantable Cardioverter Defibrillator Therapy in Heart Failure Patients With Metabolic Syndrome. Front Physiol 2018; 9:758. [PMID: 29997521 PMCID: PMC6028698 DOI: 10.3389/fphys.2018.00758] [Citation(s) in RCA: 32] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/13/2018] [Accepted: 05/30/2018] [Indexed: 11/13/2022] Open
Abstract
Background: Internal cardioverter defibrillator (ICD) therapy reduced all-cause mortality. Conversely, few studies reported that ICDs' shocks may reduce survival. Recently authors suggested that, multiple inflammatory and molecular pathways were related to worse prognosis in metabolic syndrome (MS) patients treated by ICDs. Therefore, it may be relevant to find new biomarkers to predict ICDs' shock and worse prognosis in treated patients. Methods: In 99 MS vs. 107 no MS patients treated by ICD for primary prevention, we evaluated all-cause mortality, cardiac deaths, hospitalization for heart failure, appropriate and inappropriate therapy, and survival after appropriate ICD therapy. Results: MS vs. no MS patients had higher levels of failing heart stress biomarkers. The highest values of ST2 were related to worse prognosis. Patients who had better survival after appropriate ICD therapy were those associated with lowest ST2 values. At multivariate Cox regression analysis, C reactive protein (CRP) (0.110 [0.027-0.446], p-value 0.002), troponine I (TnI) protein (0.010 [0.001-0.051], p-value 0.010), and B type natriuretic peptide (BNP) (1.151 [1.010-1.510], p-value 0.001), predicted all cause of deaths. BNP predicted cardiac deaths (1.010 [1.001-1.206], p-value 0.033). MS, and BNP predicted hospitalization for heart failure events (2.902 [1.345-4.795], p-value 0.001; 1.005 [1.000-1.016], p-value 0.007). ST2 predicted appropriate therapy (1.012 [1.007-1.260], p-value 0.001), as BNP (1.005 [1.001-1.160], p-value 0.028), LVEF (1.902 [1.857-1.950], p-value 0.001), and CRP (1.833 [1.878-1.993], p-value 0.028). ST2, and BNP predicted survival after ICD appropriate therapy (4.297 [1.985-9.302], p-value 0.001; 1.210 [1.072-1.685], p-value 0.024). Conclusions: ST2 values may differentiate MS patients with a higher risk of ICDs' therapy, and worse prognosis. Therefore, ST2 protein may be used as valid monitoring biomarker, and as a predictive biomarker in failing heart ICDs' patients affected by MS.
Collapse
Affiliation(s)
- Celestino Sardu
- Department of Medical, Surgical, Neurological, Metabolic and Aging Sciences, University of Campania “Luigi Vanvitelli”, Naples, Italy
| | - Raffaele Marfella
- Department of Medical, Surgical, Neurological, Metabolic and Aging Sciences, University of Campania “Luigi Vanvitelli”, Naples, Italy
| | - Matteo Santamaria
- Department of Cardiovascular and Arrhythmias, John Paul II Research and Care Foundation, Campobasso, Italy
| | - Stefano Papini
- Department of Cardiovascular and Arrhythmias, John Paul II Research and Care Foundation, Campobasso, Italy
| | - Quintino Parisi
- Department of Cardiovascular and Arrhythmias, John Paul II Research and Care Foundation, Campobasso, Italy
| | - Cosimo Sacra
- Department of Cardiovascular and Arrhythmias, John Paul II Research and Care Foundation, Campobasso, Italy
| | - Daniele Colaprete
- Department of Cardiovascular and Arrhythmias, John Paul II Research and Care Foundation, Campobasso, Italy
| | - Giuseppe Paolisso
- Department of Medical, Surgical, Neurological, Metabolic and Aging Sciences, University of Campania “Luigi Vanvitelli”, Naples, Italy
| | - Maria R. Rizzo
- Department of Medical, Surgical, Neurological, Metabolic and Aging Sciences, University of Campania “Luigi Vanvitelli”, Naples, Italy
| | - Michelangela Barbieri
- Department of Medical, Surgical, Neurological, Metabolic and Aging Sciences, University of Campania “Luigi Vanvitelli”, Naples, Italy
| |
Collapse
|
4
|
Marino BS, Tabbutt S, MacLaren G, Hazinski MF, Adatia I, Atkins DL, Checchia PA, DeCaen A, Fink EL, Hoffman GM, Jefferies JL, Kleinman M, Krawczeski CD, Licht DJ, Macrae D, Ravishankar C, Samson RA, Thiagarajan RR, Toms R, Tweddell J, Laussen PC. Cardiopulmonary Resuscitation in Infants and Children With Cardiac Disease: A Scientific Statement From the American Heart Association. Circulation 2018; 137:e691-e782. [PMID: 29685887 DOI: 10.1161/cir.0000000000000524] [Citation(s) in RCA: 103] [Impact Index Per Article: 17.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
Abstract
Cardiac arrest occurs at a higher rate in children with heart disease than in healthy children. Pediatric basic life support and advanced life support guidelines focus on delivering high-quality resuscitation in children with normal hearts. The complexity and variability in pediatric heart disease pose unique challenges during resuscitation. A writing group appointed by the American Heart Association reviewed the literature addressing resuscitation in children with heart disease. MEDLINE and Google Scholar databases were searched from 1966 to 2015, cross-referencing pediatric heart disease with pertinent resuscitation search terms. The American College of Cardiology/American Heart Association classification of recommendations and levels of evidence for practice guidelines were used. The recommendations in this statement concur with the critical components of the 2015 American Heart Association pediatric basic life support and pediatric advanced life support guidelines and are meant to serve as a resuscitation supplement. This statement is meant for caregivers of children with heart disease in the prehospital and in-hospital settings. Understanding the anatomy and physiology of the high-risk pediatric cardiac population will promote early recognition and treatment of decompensation to prevent cardiac arrest, increase survival from cardiac arrest by providing high-quality resuscitations, and improve outcomes with postresuscitation care.
Collapse
|
5
|
Abstract
Careful review of the literature of the last 20 years since the appearance of the first positive trials in heart failure indicates an evolution in the mode of death moving from sudden death to a predominance of pump failure death (i.e., death due to progression of heart failure). Pump failure is becoming a leading cause of mortality in a range of patient profiles, including patients with newly diagnosed or severe heart failure, patients with devices, and patients with heart failure associated with Chagas' disease. Indeed, the evidence suggests that modern management strategies, such as beta-blockers and devices, are successful in preventing sudden death. However, this means that optimally treated patients are at greater risk for the consequences of pump failure (death, hospitalization, and reduced quality of life). This highlights a new important unmet need in heart failure, and a priority for current research should be therapies that reduce pump failure death and hospitalization for more cost-effective management of the disease. Insofar as one-third of heart failure patients do not survive more than 3 years after diagnosis, properly addressing pump failure is an essential target in heart failure.
Collapse
|
8
|
Inoue T, Kawai M, Nakane T, Nojiri A, Minai K, Komukai K, Ogawa T, Hongo K, Matsushima M, Yoshimura M. Influence of low-grade inflammation on plasma B-type natriuretic peptide levels. Intern Med 2010; 49:2659-68. [PMID: 21173540 DOI: 10.2169/internalmedicine.49.4211] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
OBJECTIVE B-type natriuretic peptide (BNP) is a cardiac hormone. The results of previous in vitro studies suggest that neurohumoral factors, and not only hemodynamic factors, may cause BNP secretion. In this study, we examined the impact of serum C-reactive protein (CRP) levels on the relationship between echocardiographic parameters and plasma BNP levels in patients with cardiovascular diseases. METHODS AND PATIENTS The study population comprised 417 patients who visited our cardiovascular unit with a problem. Both blood sampling and echocardiography were performed within one month. RESULTS Multiple regression analysis showed that plasma BNP levels were negatively correlated with male gender, body mass index, and estimated glomerular filtration rate, and positively correlated with serum CRP levels and left ventricular end-systolic dimension (LVDs). The study population was divided into two groups based on the 75th percentile of the serum CRP levels. Single regression analysis showed that a regression line between LVDs and plasma BNP levels was steeper in the group of patients with CRP levels above the 75th percentile. Multiple regression analysis revealed that the interaction term (LVDs×CRP) was significant, which means LVDs had more impact on plasma BNP levels at higher CRP levels. CONCLUSION Plasma BNP levels increased with respect to the severity of cardiac dysfunction and serum CRP levels, and should therefore be considered a collective or total marker for life-threatening conditions including systemic inflammation, and not simply as a marker of cardiac dysfunction in patients with cardiovascular diseases.
Collapse
Affiliation(s)
- Terumasa Inoue
- Division of Cardiology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo
| | | | | | | | | | | | | | | | | | | |
Collapse
|